| Literature DB >> 30719398 |
William Belangero1, Jorge Daniel Barla2, Daniel Horacio Rienzi Bergalli3, Carlos Mario Olarte Salazar4, Daniel Schweitzer Fernandez5, Miguel Angel Mite Vivar6, Alejandro Zylberberg7, Guido Sebastian Carabelli2, Maurício Kfuri8.
Abstract
INTRODUCTION: Hip fracture is a common and devastating event in older adults causing increased dependence, comorbidity, and mortality. Since new surgical techniques have not significantly improved the mortality rate, a better understanding of patient risk factors could improve the treatment algorithm and outcomes. This prospective study aimed to document the 1-year survival rate of patients with intertrochanteric fracture treated surgically in Latin America and to investigate risk factors associated with 1-year mortality. PATIENTS AND METHODS: Between January 2013 and March 2015, 199 patients were prospectively enrolled. Inclusion criteria were aged 60 years or older, isolated intertrochanteric fracture (AO/OTA 31-A), and time to surgery within 10 days after injury. The follow-up period was 1 year. The association between mortality and patient demographics, comorbidity, surgical details, and preoperative laboratory parameters was assessed using log-rank tests.Entities:
Keywords: C-reactive protein; CRP; albuminemia; hip fracture; mortality; risk factor
Year: 2019 PMID: 30719398 PMCID: PMC6348579 DOI: 10.1177/2151459318816982
Source DB: PubMed Journal: Geriatr Orthop Surg Rehabil ISSN: 2151-4585
Figure 1.Patient recruitment flow diagram.
Baseline Patient Demographic and Comorbidity.
| N = 199 | |
|---|---|
| Gender, n (%) | 199 |
| Female | 175 (87.9) |
| Male | 24 (12.1) |
| Age, years, n | 199 |
| Mean (SD) | 83.5 (7.5) |
| Body mass index, kg/m2, n (%) | 197 |
| Mean (SD) | 24.4 (3.4) |
| <18.5 | 5 (2.5) |
| 18.5 to <25.0 | 112 (56.9) |
| 25.0 to <30.0 | 69 (35.0) |
| ≥30.0 | 11 (5.6) |
| ENRICHD social support inventory score, n (%) | 194 |
| Mean (SD) | 28.1 (4.1) |
| 6-18 | 2 (1.0) |
| 19-34 | 192 (99.0) |
| Barthel Index, n | 199 |
| Mean (SD) | 84.0 (18.5) |
| Mini-Mental State Examination score, n | 197 |
| Mean (SD) | 21.4 (6.5) |
| ≤9 | 16 (8.1) |
| 10-20 | 48 (24.4) |
| 21-24 | 62 (31.5) |
| 25-30 | 71 (36.0) |
| Charlson Comorbidity Index,a n (%) | 197 |
| Median (Q1; Q3) | 1.0 (0.0; 1.0) |
| 0 | 97 (49.2) |
| 1 | 52 (26.4) |
| 2 | 24 (12.2) |
| 3 | 15 (7.6) |
| 4 | 6 (3.0) |
| 5 | 2 (1.0) |
| 6 | 1 (0.5) |
| ASA score, n (%) | 199 |
| I A normal healthy patient | 5 (2.5) |
| II A patient with mild systemic disease | 133 (66.8) |
| III A patient with severe systemic disease | 56 (28.1) |
| IV A patient with severe systemic disease that is a constant threat to life | 5 (2.5) |
| Place of residence prior to admission, n (%) | 199 |
| At home without support (independent) | 153 (76.9) |
| At home with caregiver support | 40 (20.1) |
| Nursing home | 5 (2.5) |
| Other | 1 (0.5) |
Abbreviations: ASA, American Society of Anesthesiologists; ENRICHD, ENhancing Recovery In Coronary Heart Disease patients.
aThe minimum possible score is 0 and maximum, 29. A higher score indicates a greater burden of comorbid conditions. ENRICHD social support inventory: The scores range from 6 to 34; higher scores indicate greater level of social support. Scores between 6 and18: low social support, 19-34: reasonable social support. Barthel Index measures patients' functional independence in activities of daily living. Scores range from 0-100; higher score reflects greater degree of independence. Mini-Mental State Examination evaluates patients' cognitive state; scores range from 0 to 30; lower scores indicate greater deficits. Scores greater than or equal to 25 points: effectively normal. Scores ≤ 9 points: severe cognitive impairment, 10-20 points: moderate cognitive impairment, 21-24 points: mild cognitive impairment. Charlson Comorbidity Index: Scores range from 0 to 29. A higher score indicates a greater burden of comorbid conditions.
Injury and Surgical Details.
| N = 199 | |
|---|---|
| AO fracture classification, n (%) | |
| AO 31-A1 | 59 (29.6) |
| AO 31-A2 | 114 (57.3) |
| AO 31-A3 | 26 (13.1) |
| Fracture type, n (%) | |
| Closed | 199 (100.0) |
| Open | 0 (0.0) |
| Time from injury to hospital admission (days) | |
| Median (Q1; Q3) | 0.0 (0.0; 0.0) |
| Time from injury until surgery (days) | |
| Mean (SD) | 2.2 (1.8) |
| Type of anesthesia, n (%) | |
| General | 51 (25.6) |
| Regional | 148 (74.4) |
| Duration of surgery (skin-to-skin time, minutes), n | |
| Mean (SD) | 55.4 (24.8) |
| Duration of hospital stay (nights) | |
| Median (Q1; Q3) | 7.0 (5.0; 10.0) |
| Implant type, n (%) | |
| Nail | 151 (75.9) |
| Plate | 25 (12.6) |
| Plate MIPO | 23 (11.6) |
Abbreviation: MIPO, minimally invasive plate osteosynthesis; SD, standard deviation.
Figure 2.One-year survival rate: Kaplan-Meier analysis with number of patients at risk.
*Thirty-seven patients completed their 1-year visit too early (259–364 days after surgery), therefore the number of patients at risk at 365 days was 137 patients.
Cause of Deaths Within 365 Days After Surgery.
| Adverse Event (AE) | N = 20a |
|---|---|
| AE that lead to death, n (%) | 20 |
| Sepsis | 1 |
| Pneumonia | 2 |
| Bleeding (gastrointestinal, cerebral) | 1 |
| Cardiac (myocardial infarction, new arrhythmia) | 1 |
| Stroke | 1 |
| Unknown respiratory failure | 1 |
| Symptomatic hyponatremia | 1 |
| Heart failure, multiple organ dysfunction syndrome | 1 |
| Pancreas carcinoma | 1 |
| Bedsores | 1 |
| Acute pulmonary oedema | 1 |
| Bowel obstruction | 1 |
| Cardiogenic shock | 2 |
| Diabetic ketoacidosis | 1 |
| Unknown | 4 |
aOne patient died after the 365 days visit was done. As the death was caused by an adverse event started before the 365 days visit, the death was included in the analysis.
Figure 3.One-year mortality analyses: Kaplan-Meier curve with number of patients at risk.
*The cut-off point for the Mini-Mental State Examination was set at 23 based on the prevailing opinion and usage.[31]
Association Between Potential Risk Factors and 1-Year Mortality.
| Risk Factor | n | 365 Days Survival in % (95% Cl) |
|
|---|---|---|---|
| Age | .032 | ||
| 60-<85 years | 100 | 93.9 (86.9-97.2) | |
| ≥85 years | 99 | 85.6 (76.9-91.2) | |
| Gender | .393 | ||
| Female | 175 | 90.7 (85.3-94.2) | |
| Male | 24 | 83.3 (61.5-93.4) | |
| Body mass index | .973 | ||
| <25 | 117 | 90.4 (83.4-94.6) | |
| ≥25 | 80 | 88.6 (79.2-93.9) | |
| History of diabetes | .229 | ||
| No | 125 | 91.9 (85.5-95.6) | |
| Yes | 45 | 84.2 (69.6-92.1) | |
| Cardiovascular disease | .109 | ||
| No | 168 | 91.6 (86.3-94.9) | |
| Yes | 31 | 79.5 (59.9-90.3) | |
| Charlson comorbidity index | .002 | ||
| >0 | 100 | 84.6 (75.8-90.4) | |
| 0 | 97 | 95.9 (89.3-98.4) | |
| Parker Mobility Score (baseline) | .026 | ||
| ≤6 | 83 | 83.8 (73.7-90.3) | |
| 7-9 | 116 | 94.0 (87.8-97.1) | |
| Cognitive impairment according to Mini-Mental State Examinationa | .040 | ||
| No (MMSE > 23) | 85 | 94.1 (86.4-97.5) | |
| Yes (MMSE ≤ 23) | 112 | 86.3 (78.3-91.5) | |
| AO fracture classification | .216 | ||
| AO 31-A1 | 59 | 94.9 (85.1-98.3) | |
| AO 31-A2 | 114 | 88.5 (81.0-93.2) | |
| AO 31-A3 | 26 | 83.9 (62.6-93.7) | |
| Time between injury and surgery (days) | .735 | ||
| ≤2 days | 142 | 90.8 (84.7-94.6) | |
| ≥3 days | 57 | 87.2 (75.0-93.7) | |
| Type of anesthesia | .369 | ||
| General | 51 | 92.0 (80.0-96.9) | |
| Regional | 148 | 89.0 (82.7-93.1) | |
| Preoperative plasma troponin T levelb within reference range | .742 | ||
| No | 48 | 91.6 (79.1-96.8) | |
| Yes | 124 | 88.6 (81.6-93.1) | |
| Preoperative creatinine clearance | .202 | ||
| Standardized creatinine clearance ≥ 30, mL/min | 115 | 92.0 (85.3-95.8) | |
| Standardized creatinine clearance < 30, mL/min | 81 | 86.3 (76.6-92.1) | |
| Preoperative blood sodium levelb | .213 | ||
| Within reference range | 155 | 91.5 (85.8-95.0) | |
| Too low | 38 | 86.8 (71.2-94.3) | |
| Preoperative blood potassium levelb within reference range | .335 | ||
| No | 27 | 85.2 (65.2-94.2) | |
| Yes | 166 | 91.4 (86.0-94.8) | |
| Preoperative plasma albumin levelb | .007 | ||
| Within reference range | 154 | 92.8 (87.4-96.0) | |
| Too low | 22 | 76.6 (52.5-89.5) | |
| Preoperative blood C-reactive protein levelb within reference range | .012 | ||
| No | 114 | 87.5 (79.9-92.4) | |
| Yes | 58 | 98.3 (88.4-99.8) |
Abbreviation: MMSE, Mini-Mental State Examination.
aThe cut-off point for the Mini-Mental State Examination (MMSE) was set at 23 based on the prevailing opinion and usage.[31]
Patient Recovery During Follow-Up.
| Visit | Mean (95% CI) | Change (95% CI)a |
|
|---|---|---|---|
| Parker Mobility Scoreb | |||
| Preinjury, n = 199 | 6.70 (6.35-7.05) | ||
| 90 days, n = 139 | 4.72 (4.33-5.11) | −1.98 (−2.40 to −1.55) | <.001 |
| 365 days, n = 156 | 5.67 (5.31-6.04) | −1.02 (−1.42 to −0.63) | <.001 |
| Modified Harris Hip Score | |||
| Preinjury, n = 198 | 81.6 (78.7-84.6) | ||
| 90 days, n = 143 | 70.8 (68.1-73.5) | −10.8 (−14.4 to −7.3) | <.001c |
| EQ-5D index scoreb | |||
| Preinjury, n = 198 | 0.71 (0.67-0.76) | ||
| 90 days, n = 143 | 0.60 (0.56-0.65) | −0.11 (−0.16 to −0.06) | <.001 |
| 365 days, n = 155 | 0.69 (0.65-0.74) | −0.02 (−0.08 to 0.03) | .444 |
| EQ-5D VASb | |||
| Preinjury, n = 192 | 67.8 (65.1-70.5) | ||
| 90 days, n = 121 | 67.8 (64.4-71.3) | 0.1 (−3.7 to 3.8) | .977 |
| 365 days, n = 137 | 73.0 (70.4-75.6) | 5.2 (1.6 to 8.9) | .005 |
Abbreviations: CI, confidence interval; VAS, visual analogue scale.
aChange refers to change from the baseline (preinjury) value.
bEstimates, confidence intervals and p-values derived from a mixed model for repeated measures with an unstructured covariance.
cpaired t-test Parker Mobility Score (PMS) is a composite score of the patient's ability to perform indoor walking, outdoor walking, and shopping. PMS ranges 0 (no walking ability at all) to 9 (fully independent) (Parker and Palmer[28], 1993). Modified Harris Hip Score (MHHS) assesses hip pain and function (Harris[27], 1969; Byrd and Jones[49], 2000), and has a range of 0 = 100. EQ-5D index score ranges from 0 (dead) to 1 (perfect health) (Herdman et al[50], 2011, EuroQol Group[29], 1990), although negative values are possible.
Summary of Adverse Events (Patient-Level).
| Adverse Events | n | %a (95% CIb) | Action Taken, n (%) | ||
|---|---|---|---|---|---|
| No Action | Nonoperative | Operative | |||
| Any adverse event | 88 | 44.2 (37.2-51.4) | 10 (11.6) | 57 (66.3) | 19 (22.1) |
| Cut-out of blade/screw | 0 | 0.0 (0.0-1.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Cut-through of blade/screw | 4 | 2.0 (0.6-5.1) | 1 (25.0) | 0 (0.0) | 3 (75.0) |
| Poor intraoperative fracture reduction | 0 | 0.0 (0.0-1.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Loss of reduction with nail/screw insertion | 3 | 1.5 (0.3-4.3) | 1 (33.3) | 0 (0.0) | 2 (66.7) |
| Iatrogenic operative femoral fracture(s) | 0 | 0.0 (0.0-1.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Delayed union, nonunion | 1 | 0.5 (0.0-2.8) | 0 (0.0) | 0 (0.0) | 1 (100.0) |
| Malunion/loss of reduction leading to malalignment of the femur in frontal plane: varus/valgus | 1 | 0.5 (0.0-2.8) | 0 (0.0) | 0 (0.0) | 1 (100.0) |
| Irritation of the tractus iliotibialis | 1 | 0.5 (0.0-2.8) | 0 (0.0) | 0 (0.0) | 1 (100.0) |
| Deep wound infection | 1 | 0.5 (0.0-2.8) | 0 (0.0) | 0 (0.0) | 1 (100.0) |
| Superficial wound infection | 2 | 1.0 (0.1-3.6) | 0 (0.0) | 2 (100.0) | 0 (0.0) |
| Wound dehiscence | 1 | 0.5 (0.0-2.8) | 0 (0.0) | 1 (100.0) | 0 (0.0) |
| Hematoma (requiring revision) | 0 | 0.0 (0.0-1.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Thromboembolic complications | 7 | 3.5 (1.4-7.1) | 0 (0.0) | 6 (85.7) | 1 (14.3) |
| Sepsis | 3 | 1.5 (0.3-4.3) | 0 (0.0) | 2 (66.7) | 1 (33.3) |
| Pneumonia | 6 | 3.0 (1.1-6.4) | 1 (16.7) | 5 (83.3) | 0 (0.0) |
| Renal insufficiency | 0 | 0.0 (0.0-1.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Bleeding (gastrointestinal, cerebral) | 3 | 1.5 (0.3-4.3) | 0 (0.0) | 3 (100.0) | 0 (0.0) |
| Cardiac (myocardial infarction, new arrhythmia) | 7 | 3.5 (1.4-7.1) | 1 (14.3) | 6 (85.7) | 0 (0.0) |
| Stroke | 4 | 2.0 (0.6-5.1) | 0 (0.0) | 4 (100.0) | 0 (0.0) |
| Other systemic adverse eventc | 70 | 35.2 (28.6-42.2) | 12 (17.6) | 44 (64.7) | 12 (17.6) |
Abbreviation: CI, confidence interval.
Note: Only adverse events with onset before upper 1-year follow-up window (i.e., <= 425 days after surgery) were included.
aEstimated risk of developing at least one complication (calculated by dividing the number of patients experiencing at least one complication by the total number of patients.
bConfidence intervals were calculated using the exact method.
cThese included conditions such as urinary tract infection, anemia, respiratory problems, and new fractures.